Brief: CytRx Highlights Orphazyme's Receipt Of FDA Acceptance & Priority Review Of NDA For Arimoclomol
17/09/2020 14:31
Sept 17 (Reuters) - CytRx Corp CYTR.PK :
* CYTRX HIGHLIGHTS ORPHAZYME’S RECEIPT OF FDA ACCEPTANCE AND
PRIORITY REVIEW OF ITS NEW DRUG APPLICATION FOR ARIMOCLOMOL FOR
NIEMANN-PICK DISEASE TYPE C
Source text for Eikon: ID:nBw5C7JHfa
Further company coverage: CYTR.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C